Pliant Therapeutics Inc
$ 1.13
-1.74%
12 Feb - close price
- Market Cap 69,438,000 USD
- Current Price $ 1.13
- High / Low $ 1.15 / 1.11
- Stock P/E N/A
- Book Value 3.26
- EPS -2.86
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.64 %
- 52 Week High 3.46
- 52 Week Low 1.09
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$3.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-07 | 2024-05-06 | 2024-02-27 | 2023-11-09 | 2023-08-09 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -0.43 | -0.71 | -0.92 | -0.82 | -0.95 | -0.92 | -0.78 | -0.69 | -0.7 | -0.7 | -0.67 | -0.72 |
| Estimated EPS | -0.56 | -0.6595 | -0.7469 | -0.9552 | -0.97 | -0.85 | -0.77 | -0.81 | -0.77 | -0.71 | -0.67 | -0.7 |
| Surprise | 0.13 | -0.0505 | -0.1731 | 0.1352 | 0.02 | -0.07 | -0.01 | 0.12 | 0.07 | 0.01 | 0 | -0.02 |
| Surprise Percentage | 23.2143% | -7.6573% | -23.1758% | 14.1541% | 2.0619% | -8.2353% | -1.2987% | 14.8148% | 9.0909% | 1.4085% | 0% | -2.8571% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLRX
2026-02-09 22:59:55
The Idiopathic Pulmonary Fibrosis (IPF) market is projected to expand significantly, with a market size of approximately USD 3,300 million in 2023. Key companies like Boehringer Ingelheim, PureTech, and others are developing new therapies, including BI 765423 and Jascayd Registered (nerandomilast/BI 1015550), and conducting clinical trials to address the increasing prevalence of IPF. The report highlights market drivers such as advancing R&D and improved diagnostics, alongside barriers like high treatment costs and late diagnoses.
2026-01-23 18:27:59
Pliant Therapeutics' Chief Human Resource Officer Lily Cheung sold 7,534 shares of common stock for $9,643 on January 20, 2026, bringing her direct ownership to 44,847 shares. The company recently reported positive interim Phase 1 data for its cancer drug PLN-101095 and announced executive changes, including the appointment of Minnie Kuo as chief operating officer and the departure of its chief medical officer and chief business officer.
2026-01-23 06:57:51
Pliant Therapeutics President and CEO Bernard Coulie sold 89,375 shares of common stock for approximately $114,400, primarily to cover withholding tax obligations related to restricted stock units. Following this transaction, Coulie retains direct ownership of 505,601 shares and indirect ownership of 409,317 shares through a family trust. The company also announced encouraging interim Phase 1 trial data for its cancer drug PLN-101095 and notable leadership changes.
2026-01-23 06:29:10
Lily Cheung, CHRO of Pliant Therapeutics (NASDAQ:PLRX), sold 7,534 shares of company stock for $9,643 on January 20, 2026. This transaction leaves her with 44,847 shares. The sale follows other recent company news, including positive interim data from a Phase 1 cancer drug trial and significant personnel changes.
2026-01-23 04:00:00
Pliant Therapeutics' CHRO, Lily Cheung, sold 7,534 shares of common stock for $9,643 on January 20, 2026, and now directly owns 44,847 shares. In other news, the company reported positive interim Phase 1 data for its cancer drug PLN-101095 and announced several personnel changes, including the appointment of Minnie Kuo as COO and the departures of Dr. Éric Lefebvre and Hans Hull.
2026-01-23 03:27:32
Bernard Coulie, CEO of Pliant Therapeutics (NASDAQ:PLRX), sold 89,375 shares of the company's stock on January 20th for approximately $114,400. This transaction reduced his ownership by 15.02%, leaving him with 505,601 shares valued at about $647,169. The stock is currently trading around $1.30, with analysts giving it a "Reduce" rating and an average target price of $3.93.
